DrugPipeline.net has announced the addition of “US Market Report for Dental Growth Factor 2017 - MedCore” research report to their website www.DrugPipeline.net
Bangalore, India -- (SBWIRE) -- 07/24/2017 -- General Report Contents
- Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
- Market Drivers & Limiters for each chapter segment
- Competitive Analysis for each chapter segment
- Section on recent mergers & acquisitions
Most of the new products in this area are derived from advances made in the orthopedic field. However, adapting an orthopedic product for dental applications is not straightforward – a separate approval must be obtained from the U.S. Food and Drug Administration (FDA) for dental use. This has created a significant delay between when products are introduced to the orthopedic market and when they enter the dental market.
Dental growth factor products currently offered to the U.S. market in 2016 were GEM 21S®, INFUSE®, Osteocel® and Emdogain™. Over the forecast period, a number of additional growth factor combinations are expected to enter the tissue engineering product market. In 2005, the FDA approved the release of BioMimetic's GEM 21S®, the first growth factor matrix approved for dental use. The product has since gained traction and received the CE mark approval to enter the European market in 2012.
In late 2006, Medtronic's INFUSE®, a growth factor containing bone graft product, was also approved for dental use. Tissue engineering products are often employed in combination with bone graft substitutes. Certain products cater to a specific need; for that reason, the various growth factors in the market are not viewed as complete substitutes or directly in competition with one another.
Osteoinductivity refers to the ability of a graft to induce non-differentiated stem cells, or osteoprogenitor cells, to differentiate into osteoblasts, resulting in bone regeneration. However, only a few bone graft substitute materials have the capacity for osteoconductivity. Growth factors and other tissue engineering products enhance osteoconductivity, and are used to increase the rate and volume of bone regeneration.
Dental growth factor and tissue engineering products is a broad category that encompasses products used for facilitating and enhancing bone regeneration. This includes growth factors and enamel matrix protein solutions. Platelet rich plasma (PRP) is also used for these purposes, but will not be considered within this report.
Spanning over 227 pages "US Market Report for Dental Growth Factor 2017 - MedCore" report covers Executive Summary, Research Methodology, Disease Overview, Product Assessment, Dental Growth Factor Market, Appendix. This Report Covered Companies Few Are - Geistlich, Zimmer Biomet, Ace Surgical, Biohorizons, Tissue Banks, Osteogenics, Lifenet Health, Dentsply Sirona, Salvin, Straumann, Osteohealth.
For more information Visit at: http://www.drugpipeline.net/idata-research/us-market-report-dental-growth-factor-2017-medcore
Find all Pharma and Healthcare Reports at - http://www.drugpipeline.net/catalog/pharma-healthcare
US Procedure Numbers for Dental Bone Graft Substitutes and Other Biomaterials 2017 - MedPro - Visit at - http://www.drugpipeline.net/idata-research/us-procedure-numbers-dental-bone-graft-substitutes-and-other-biomaterials-2017-medpro
US Product Portfolio for Dental Bone Graft Substitutes and Other Biomaterials 2017 - MedFolio - Visit at - http://www.drugpipeline.net/idata-research/us-product-portfolio-dental-bone-graft-substitutes-and-other-biomaterials-2017
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.